32 results
8-K
EX-99.1
ZLAB
Zai Lab Limited
8 May 24
Zai Lab Announces First Quarter 2024
4:09pm
):
–In April 2024, Zai Lab submitted an sBLA for efgartigimod SC for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP … to initiate a global Phase 2 study in mild-to-moderate chronic plaque psoriasis in the second quarter of 2024.
Conference Call and Webcast Information
8-K
EX-99.1
4s8392r4
27 Feb 24
Zai Lab Announces Full-Year 2023
4:12pm
8-K
EX-99.1
ysatehmjq akl
7 Nov 23
Zai Lab Announces Third Quarter 2023
4:10pm
8-K
EX-99.1
6w4wztxdenof
7 Aug 23
Zai Lab Announces Second Quarter 2023
4:07pm
8-K
EX-99.1
iypo 7bmk5siwb9
30 Jun 23
Zai Lab and argenx Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China
4:18pm
8-K
EX-99.1
zkqx5j w7hkjmq
9 May 23
Zai Lab Announces First Quarter 2023
4:03pm
8-K
EX-99.1
nii81tfsa7m8f5x69bzq
9 Nov 22
Zai Lab Announces Third Quarter 2022
4:13pm
8-K
EX-99.1
3jzc52v o7sz5r0rdr
9 Aug 22
Zai Lab Announces Second Quarter 2022
12:00am
8-K
EX-99.1
2jszg4wilskio
10 May 22
Zai Lab Announces First Quarter 2022
4:10pm
8-K
EX-99.1
co7 rfb2scs
1 Mar 22
Results of Operations and Financial Condition
4:17pm